Table 4. Comparison of performances of TFPI2 and CA125 in discriminating CCC patients from other patient groups.

Discrimination	Biomarker	Sample set	No. of samples (No. of CCC)	AUC	95% CI	Cut-off value	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Accuracy (%)
CCC vs other ovarian diseases	TFPI2	Training set	230 (29)	0.893	0.812 to 0.972	345 pg/mL	79.3	91.0	56.1	96.8	89.6
		Validation set	93 (7)	0.817	0.597 to 1.000		71.4	91.9	45.5	97.5	90.3
	CA125	Training set	230 (29)	0.595	0.501 to 0.688	35 U/mL	79.3	41.8	16.9	93.3	46.5
		Validation set	93 (7)	0.785	0.589 to 0.981		85.7	43.0	12.8	97.4	46.2
CCC vs BD + other EOCs	TFPI2	Training set	116 (29)	0.854	0.761 to 0.952	345 pg/mL	79.3	85.1	63.9	92.5	83.6
		Validation set	53 (7)	0.797	0.558 to 1.035		71.4	85.7	50.0	94.7	83.7
	CA125	Training set	116 (29)	0.639	0.533 to 0.745	35 U/mL	79.3	18.4	25.6	72.7	33.6
		Validation set	53 (7)	0.708	0.493 to 0.923		85.7	19.0	18.8	88.9	28.6
CCC vs EMS	TFPI2	Training set	100 (29)	0.924	0.843 to 0.997	280 pg/mL	82.8	93.0	82.8	93.0	90.0
		Validation set	24 (7)	0.807	0.561 to 1.052		71.4	100	100	89.5	91.7
	CA125	Training set	100 (29)	0.700	0.584 to 0.817	35 U/mL	79.3	43.7	36.5	83.8	54.0
		Validation set	24 (7)	0.803	0.545 to 1.060		85.7	23.5	31.6	80.0	41.7
All EOCs vs BN	CA125	Training set	230 (116*)	0.814	0.760 to 0.869	35 U/mL	81.0	55.3	64.8	74.1	68.3
		Validation set	93 (53*)	0.761	0.664 to 0.857		75.5	62.5	72.7	65.8	69.9

Abbreviations: BD, borderline ovarian tumor; EMS, endometriosis; BN, benign ovarian tumor. Asterisks indicate numbers of EOC patients.